Loading clinical trials...
Loading clinical trials...
A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria
Conditions
Interventions
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
+1 more
Locations
93
United States
Research Site
Sheffield, Alabama, United States
Research Site
Glendale, California, United States
Research Site
Waterbury, Connecticut, United States
Research Site
Hialeah, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Annapolis, Maryland, United States
Start Date
May 1, 2024
Primary Completion Date
May 9, 2025
Completion Date
May 9, 2025
Last Updated
May 16, 2025
NCT05398783
NCT07547098
NCT05196035
NCT07232537
NCT06721143
NCT06278207
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions